Bryce Allen PhD

​Bryce Allen, Ph.D. is the co-founder and CEO of Differentiated Therapeutics (dx/tx), a company combining breakthroughs in biophysics, chemo proteomics, molecular simulation, AI, and automation to map the conformational basis of induced proximity and use that map to design novel degrader therapeutics. Previously, he was the founding Head of Integrated Data Sciences at Silicon Therapeutics and played a key role in building the company from three employees to over one hundred, culminating in its acquisition by Roivant Sciences in 2021, driven in large part by the cutting-edge computational platform. During that period he spearheaded the development and application of the computational platform to drug discovery projects. He played a leading role in the discovery and optimization of SNX281, a first-in-class small molecule STING agonist currently in phase I clinical trials, taking the program from an initial AI-discovered hit to a clinical candidate in <3 years.

Starting his career at the bench, Bryce has accumulated domain expertise across biology, medicinal chemistry, physics, and computer science enabling the development of practical computer-aided discovery to drive data-driven decision-making in drug development programs. He holds an Adjunct Faculty appointment in The Institute for Experiential AI at Northeastern University in Boston, MA and is the author of >30 publications and patents. Bryce was a Postdoctoral Fellow in the Department of Biomedical Informatics at Harvard Medical School and holds a Ph.D. in Molecular & Cellular Pharmacology from the University of Miami Miller School of Medicine.